IGFBP7 for prediction of risk of AKI when measured prior to surgery

US11397187B2 · kind B2 · utility

Assignee

• Roche Diagnostics Operations, Inc. · US

Inventors

• Andrea Horsch · Luzern, CH
• Birgit Klapperich · Risch, CH
• Dirk Block · Bichl, DE
• Alfred Engel · Tutzing, DE
• Johann Karl · Peißenberg, DE
• Rosemarie Kientsch-Engel · Feldafing, DE
• Ekaterina Manuilova · Penzberg, DE
• Christina Rabe · Bad Heilbrunn, DE
• Sandra Rutz · Penzberg, DE
• Monika Soukupova · Wessobrunn, DE
• Ursula-Henrike Wienhues-Thelen · Krailling, DE
• Peter Kastner · Murnau am Staffelsee, DE
• Edelgard Kaiser · Chur, CH

Key dates

• Filing date: Apr 2, 2018
• Grant date: Jul 26, 2022
• Expiry date: Jun 11, 2038

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2800/50
• WIPO field: Measurement
• WIPO sector: Instruments

Abstract

The present disclosure describes a method for predicting the risk of a patient to suffer from acute kidney injury (AKI) during or after a surgical procedure or after administration of a contrast medium. The method is based on the determination of the level of the biomarker IGFBP7 (Insulin-like Growth Factor Binding Protein 7) in a body fluid sample obtained from the patient prior to the surgical procedure or prior to the administration of a contrast medium. Further, the present disclosure describes a method for predicting the risk of a patient to suffer from acute kidney injury (AKI) based on the determination of the amount of the biomarker IGFBP7 (Insulin-like Growth Factor Binding Protein 7) and Cystatin C in a body fluid sample obtained from the patient. The present disclosure further encompasses kits and devices adapted to carry out the methods of the disclosed methods.